CagriSema Results: What Studies Measured and When
What published studies measured for CagriSema, when those outcomes were measured, and what is still unproven.
Medical review pendingAmylin + GLP-1 combinationUpdated
What studies measured
Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Body weight vs semaglutide alone | Body weight changed by -18·4% with CagriSema versus -11·9% with semaglutide alone at week 68 (difference -6·5 percentage points). | Human RCTn = 331 | The lancet. Diabetes & endocrinology 2026, PMID 42009015 |
| HbA1c at week 40 (primary) | HbA1c changed by -1·8 percentage points (2·4 mg each) and -1·5 (1·0 mg each) versus -0·1 with placebo at 40 weeks. | Human RCTn = 189 | The lancet. Diabetes & endocrinology 2026, PMID 42251860 |
| Body weight at week 40 | Body weight changed by -13·8% with CagriSema (2·4 mg each) versus -1·4% with placebo. | Human RCTn = 189 | The lancet. Diabetes & endocrinology 2026, PMID 42251860 |
| HbA1c vs semaglutide (primary) | HbA1c fell by -1·91 percentage points with CagriSema versus -1·75 with semaglutide 2·4 mg (difference -0·16). | Human RCTn = 2713 | The lancet. Diabetes & endocrinology 2026, PMID 42251859 |
| HbA1c at week 40 (primary) | HbA1c fell by -2·33% (2·4 mg each) and -2·10% (1·0 mg each) versus -0·66% with placebo at week 40 as add-on to basal insulin. | Human RCTn = 274 | Lancet 2026, PMID 42251856 |
| Body weight | CagriSema provided body weight reductions of 10-12%. | Human RCTn = 274 | Lancet 2026, PMID 42251856 |
| Blood pressure | Systolic BP changed by -10.9 mm Hg with CagriSema versus -2.8 with placebo; diastolic BP by -5.4 versus -1.7 mm Hg at week 68. | Human RCTn = 3417 | Hypertension 2026, PMID 41328546 |
| Reaching BMI and waist-to-height targets | 30.3% reached both BMI under 27 and waist-to-height ratio under 0.53 with CagriSema, versus 19.1% semaglutide, 9.0% cagrilintide and 3.3% placebo. | Human controlled trial | Diabetes, obesity & metabolism 2026, PMID 42503495 |
| Body weight at week 68 (coprimary) | Body weight changed by -20.4% with CagriSema versus -3.0% with placebo at week 68 (difference -17.3 percentage points). | Human RCTn = 3417 | The New England journal of medicine 2025, PMID 40544433 |
| Body weight at week 68 (primary) | Body weight changed by -13.7% with CagriSema versus -3.4% with placebo at week 68 (difference -10.4 percentage points). | Human RCTn = 1206 | The New England journal of medicine 2025, PMID 40544432 |
| HbA1c of 6.5% or less | 73.5% reached a glycated hemoglobin level of 6.5% or less with CagriSema versus 15.9% with placebo. | Human RCTn = 1206 | The New England journal of medicine 2025, PMID 40544432 |
| HbA1c at week 32 (primary) | HbA1c changed by -2·2 percentage points with CagriSema, -1·8 with semaglutide and -0·9 with cagrilintide; the difference was significant versus cagrilintide but not versus semaglutide. | Human RCTn = 92 | Lancet 2023, PMID 37364590 |
| Body weight at week 32 | Body weight changed by -15·6% with CagriSema, -5·1% with semaglutide and -8·1% with cagrilintide at week 32. | Human RCTn = 92 | Lancet 2023, PMID 37364590 |
| Body weight at week 20 (with semaglutide 2.4 mg) | Combined with semaglutide, body weight fell by 15·7% (cagrilintide 1·2 mg) and 17·1% (2·4 mg) versus 9·8% with pooled placebo at week 20. | Human RCTn = 96 | Lancet 2021, PMID 33894838 |
| Weight loss vs semaglutide | CagriSema produced a mean difference of -7.47% (-7.60 kg) greater weight loss than semaglutide. | Meta-analysisn = 3545 | Diabetes, obesity & metabolism 2026, PMID 41834765 |
| Weight, waist, blood pressure and HbA1c | Versus placebo, CagriSema reduced body weight by a mean difference of -5.98% (-4.68 kg) and waist circumference by -10.91 cm, with reductions in systolic blood pressure and HbA1c. | Meta-analysisn = 5425 | Annals of medicine and surgery 2026, PMID 42583410 |
- CagriSema (cagrilintide plus semaglutide) is an investigational Novo Nordisk product, not FDA-approved as of 2 October 2026. Registered phase 3 trials: REDEFINE 1 (NCT05567796), REDEFINE 2 (NCT05394519), REDEFINE 3 (NCT05669755, cardiovascular outcomes, no results found).
- REDEFINE 1 and 2 are the pivotal obesity papers (NEJM 2025). The REIMAGINE 1-3 type 2 diabetes phase 3 trials and REDEFINE 5 (Japan and Taiwan) were published in 2026.
- Half-life values are from the phase 1b co-administration trial (cagrilintide 159-195 h; semaglutide 2.4 mg 145-165 h). A fixed-dose CagriSema pharmacokinetic study was not found.
- No evidence was extracted for liver health, cholesterol or osteoporosis.
Typical timeline
When the studies above measured their outcomes. This is the study schedule, not a promise of when anyone will notice a change.
| When | What was measured | Study type | Source |
|---|---|---|---|
| 68 weeks | Coprimary endpoints: relative change in body weight and 5% or more weight reduction | Human RCTn = 3417 | The New England journal of medicine 2025, PMID 40544433 |
| 68 weeks | Primary endpoints: percent change in body weight and 5% or more weight reduction | Human RCTn = 1206 | The New England journal of medicine 2025, PMID 40544432 |
| 32 weeks | Primary endpoint: change in HbA1c | Human RCTn = 92 | Lancet 2023, PMID 37364590 |
| Week 19-20 | Pharmacokinetic sampling window (last dose to end of treatment) | Human RCTn = 96 | Lancet 2021, PMID 33894838 |
Before-and-after photos
We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.
Weight results in obesity trials
REDEFINE 1 found a mean weight change of -20.4% with CagriSema against -3.0% with placebo at week 68, in adults without diabetes.[7]
In REDEFINE 5 (Japan and Taiwan) the combination reached -18.4% against -11.9% with semaglutide over 68 weeks.[1]
In REDEFINE 1 the combination group was also more likely than placebo to reach weight-loss targets of 5% or more, 20% or more, 25% or more and 30% or more.[7]
In a post hoc analysis, 30.3% of participants on CagriSema reached both BMI and waist-to-height targets, against 3.3% on placebo.[6]
Results in type 2 diabetes
In people with type 2 diabetes in REIMAGINE 1, weight fell 13.8% at 2.4 mg each against 1.4% for placebo at 40 weeks.[2]
REIMAGINE 2 reported a baseline HbA1c of 8.2%, and the combination beat semaglutide 2.4 mg by 0.16 percentage points.[3]
Earlier-phase timepoints
In the phase 2 trial the HbA1c change at week 32 was -2.2 percentage points for CagriSema against -0.9 for cagrilintide.[9]
Common questions
How long does CagriSema take to work?
The studies we summarise measured outcomes at set points, for example Coprimary endpoints: relative change in body weight and 5% or more weight reduction at 68 weeks; Primary endpoints: percent change in body weight and 5% or more weight reduction at 68 weeks. Timelines outside studies vary.
Do you show CagriSema before and after photos?
No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.
More on CagriSema
DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.For weight lossWhat research says about CagriSema for weight loss.How it worksTarget, mechanism and how long it acts, from the label or studies.
Sources
- 1Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.The lancet. Diabetes & endocrinology · 2026PMID 42009015Accessed 2 Oct 2026
- 2Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026PMID 42251860Accessed 2 Oct 2026
- 3Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026PMID 42251859Accessed 2 Oct 2026
- 4Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.Lancet (London, England) · 2026PMID 42251856Accessed 2 Oct 2026
- 5CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension (Dallas, Tex. : 1979) · 2026PMID 41328546Accessed 2 Oct 2026
- 6Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.Diabetes, obesity & metabolism · 2026PMID 42503495Accessed 2 Oct 2026
- 7Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
- 8Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
- 9Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 2 Oct 2026
- 10Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
- 11Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.Diabetes, obesity & metabolism · 2026PMID 41834765Accessed 2 Oct 2026
- 12Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
Found an error? Report a correction.